iBio Inc. (IBIO)
NASDAQ: IBIO
· Real-Time Price · USD
0.85
0.00 (0.06%)
At close: Oct 16, 2025, 3:59 PM
0.84
-0.75%
After-hours: Oct 16, 2025, 07:54 PM EDT
0.06% (1D)
| Bid | 0.82 |
| Market Cap | 13.98M |
| Revenue (ttm) | 375K |
| Net Income (ttm) | -20.99M |
| EPS (ttm) | -1.75 |
| PE Ratio (ttm) | -0.48 |
| Forward PE | -2.29 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 0.87 |
| Volume | 341,154 |
| Avg. Volume (20D) | 948,867 |
| Open | 0.84 |
| Previous Close | 0.85 |
| Day's Range | 0.82 - 0.87 |
| 52-Week Range | 0.56 - 6.89 |
| Beta | 0.89 |
| Ex-Dividend Date | n/a |
About IBIO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IBIO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IBIO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+0.22%
IBio shares are trading lower after the company an...
Unlock content with
Pro Subscription
3 months ago
+5.63%
iBio shares are trading higher after the company announced preclinical data in which an engineered amylin receptor agonist antibody reduced acute food intake in a mouse model of obesity by 60%.
1 year ago · proactiveinvestors.com
iBio partners with AstralBio to develop obesity treatments using AI-driven platformiBio, an AI-driven drug developer, shares surged more than 120% after it announced it has entered into a collaboration agreement with private biotech firm AstralBio to discover, engineer and develop n...
